Table 5 Demographic and laboratory features of the studied patients according to the occurrence of de novo HCC (total 1789)
Variables | Hepatocellular carcinoma | P-value | ||||
|---|---|---|---|---|---|---|
Yes, number = 16 (0.9%) | No, number = 1773 (99.1%) | |||||
Mean | SD | Mean | SD | |||
Age | 58.69 | 5.59 | 54.79 | 8.47 | 0.041 | |
Gender, number (%) | Male | 12 (75.0%) | 845 (47.9%) | 0.031 | ||
Female | 4 (25.0%) | 919 (52.1%) | ||||
Treatment status | Past interferon treatment | 0 | 0.0% | 9 | 0.5% | 0.0378 |
Naïve | 15 | 93.8% | 1652 | 97.1% | ||
DAA-experienced | 1 | 6.3% | 40 | 2.4% | ||
Fibrosis stage | F3 | 1 | 100.0% | 88 | 72.1% | – |
F4 | 0 | 0.0% | 32 | 26.2% | ||
ALT | 62.44 | 26.69 | 64.74 | 43.85 | 0.552 | |
AST | 68.50 | 26.20 | 69.30 | 42.43 | 0.492 | |
Alpha-fetoprotein | 26.52 | 30.93 | 12.96 | 25.05 | 0.075 | |
Serum albumin | 3.99 | 0.62 | 3.95 | 0.68 | 0.842 | |
Total bilirubin | 1.11 | 0.55 | 0.97 | 0.51 | 0.267 | |
Total leukocytes count × 103 | 6.08 | 2.08 | 6.08 | 4.61 | 0.524 | |
Hemoglobin | 13.77 | 2.07 | 13.57 | 4.38 | 0.554 | |
Platelets count × 103 | 124.75 | 53.13 | 142.85 | 65.91 | 0.319 | |
Serum creatinine | 0.88 | 0.19 | 1.00 | 3.36 | 0.268 | |
Total bilirubin (during treatment) | 1.22 | 0.42 | 1.09 | 0.58 | 0.060 | |
Albumin (during treatment) | 3.75 | 0.50 | 3.83 | 0.64 | 0.591 | |
PC (during treatment) | 77.39 | 10.07 | 83.35 | 12.76 | 0.091 | |
INR (during treatment) | 1.28 | 0.15 | 1.25 | 2.73 | 0.008 | |
Total leukocytes count × 103 (during treatment) | 5.48 | 2.30 | 5.64 | 3.29 | 0.748 | |
Platelets count × 103 (during treatment) | 131.57 | 60.24 | 149.20 | 68.21 | 0.405 | |
Pre-treatment ALBI score | − 2.59 | 0.53 | − 2.59 | 0.59 | 0.879 | |
Post-treatment ALBI score | − 2.55 | 0.56 | − 2.75 | 1.50 | 0.172 | |